3 results
Approved WMOCompleted
Evaluate the effects of CER-001 - adminstered as iv infusion - on plaque size/burden in arteries, plaque inflammation in the artery wall and the rate of cholesterol transport in the body
Approved WMOCompleted
Objectives:• To allow continued access to tivozanib for subjects who have participated in other tivozanib (monotherapy orcombination) protocols, who are tolerating study drug and displaying clinical benefit.• To assess long-term safety and…
Approved WMOCompleted
To assess the impact of 10 intravenous infusions of 3 mg/kg CER-001 versus placebo, given at weekly intervals, on atherosclerotic plaque volume, as measured by coronary IVUS, when administered to subjects presenting with an ACS event.